CONFERENCE PROGRAMME
for the Second NCRI Cancer Conference
8 - 11 October 2006 Birmingham UK
Event Programme

Sunday 8 October

13.00 – 15.10 Workshop

14.00 – 15.00 Mission possible: how we can beat cancer - Public Lecture
Fran Balkwill
Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK

15.15 – 15.30 Welcome Address
Mike Richards
NCRI Chairman

15.30 – 16.10 Kaposi sarcoma: model of oncogenesis - The BACR Tom Connors Lecture
Chris Boshoff
Wolfson Institute for Biomedical Research, University College London, UK

16.10 – 16.50 Clinical development of targeted molecular therapies in cancer: challenges and opportunities - The Institute of Cancer Research Lecture
Elizabeth A Eisenhauer
National Cancer Institute of Canada, Queen’s University, Canada

16.50 – 17.20 Break

17.20 – 18.00 Integrating palliative care into routine cancer care: impact on clinical and financial outcomes - The Macmillan Cancer Support Lecture
Thomas J Smith
Massey Cancer Center, Virginia Commonwealth University, USA
18.00 – 19.00  Clinical Trials Showcase -
Sponsored by Clinox Ltd

First mature analysis of the Intergroup Exemestane Study
Judith M Bliss
Institute of Cancer Research, Sutton, UK

Short course pre-operative radiotherapy is superior to a policy of selective post-operative chemoradiotherapy for resectable rectal cancer: preliminary results of the MRC CR07 trial
David Sebag-Montefiore
NCRI and MRC Clinical Trial Unit, London, UK

Inhibition of androgen synthesis by an oral, irreversible, inhibitor of CYP450c17 is safe and results in a high, durable, response rate in castration refractory prostate cancer (CRPC) patients
Johann S de Bono
Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

19.00 – 21:00  Opening Reception and Trade Exhibition

Monday 9 October
08.00 – 08.50  BACR Educational Workshop – Cancer drug discovery

09.00 – 09.10  Introduction to the Programme
Alan Ashworth
Programme Planning Committee Chairman

09.10 – 09.50  Dissecting tumour suppressor gene networks in vivo - The Paterson Institute for Cancer Research Lecture
Scott W Lowe
Watson School of Biological Sciences, Cold Spring Harbor Laboratory, USA
09.50 – 10.30 Transcriptional programming in normal and leukaemic stem and progenitor cells - The Leukaemia Research Fund Lecture
Tariq Enver
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

10.30 – 11.10 Break
Exhibition Viewing

11.10 – 11.50 Lifestyle approaches to breast cancer risk reduction: insights and opportunities - The Breakthrough Generations Lecture
Leslie Bernstein
Keck School of Medicine, University of Southern California, USA

11.50 – 12.30 Marketing: mentor or menace? - The Economic and Social Research Council Lecture
Gerard Hastings
Institute for Social Marketing and Centre for Tobacco Control Research, University of Stirling and Open University, UK

12.30 – 15.00 Lunch
Poster Session and Exhibition Viewing

13.00 – 14.00 Commercial Workshop
Sponsored by Bayer HealthCare

14.00 – 15.00 Careers/Mentoring/Grant Writing Workshops

15.15 – 17.30 Parallel Sessions

17.30 – 18.00 Break

18.00 – 18.40 Winning the war against paediatric brain tumours: a fresh look at the enemy - The CR-UK London Research Institute Lecture
Richard Gilbertson
St Jude Children’s Research Hospital, Memphis, USA
18.40 – 19.20 How telomeres tame the DNA damage response - The Beatson Institute for Cancer Research Lecture
Titia de Lange
Rockefeller University, New York, USA

19.30 – 21.00 Civic Reception
Sponsored by AstraZeneca
Poster Session

Tuesday 10 October

08.00 – 08.50 BACR Educational Workshop – Imaging of cancer targets

09.00 – 09.40 Role of stem cells and differentiated cells in the genesis of squamous cell carcinoma - The AstraZeneca Lecture
Fiona Watt
CR-UK London Research Institute, UK

09.40 – 10.20 Why we need patient recorded outcomes (PROs) to properly evaluate cancer therapy - The IBM Lecture
Lesley Fallowfield
Brighton and Sussex Medical School, University of Sussex, UK

10.20 – 11.00 Break
Exhibition Viewing

11.00 – 11.40 Radiation oncology in evolution: from empirical to targeted therapy - The Ludwig Institute for Cancer Research Lecture
W Gillies McKenna
Institute for Radiation Biology Research, University of Oxford, UK

11.40 – 12.20 Selecting lung cancer patients for EGFR targeted therapies - The Cancer Research Technology Lecture
Kenneth Hillan
Genentech, Inc., San Francisco, USA
12.20 – 15.00  Lunch
Poster Session and Exhibition Viewing

13.00 – 14.00  Commercial Workshop
Sponsored by Affymetrix

14.00 – 15.00  Careers/Mentoring/Grant Writing
Workshops

15.15 – 17.30  Parallel Sessions

17.30 – 18.00  Break

18.00 – 18.40  Controlling cancer: a whole systems approach - The CR-UK Cambridge Research Institute Lecture
Harry Burns
Chief Medical Officer for Scotland, St Andrew’s House, Edinburgh, UK

18.40 – 19.20  Modelling lung cancer in the mouse -
The Cancer Research UK Lecture
Tyler Jacks
MIT Center for Cancer Research, Massachusetts Institute of Technology, USA

20.00 – 20.30  Drinks Reception

20.30 – 02.00  Conference Dinner and Party
Sponsored by Novartis Pharmaceuticals
UK Limited and Roche

Wednesday 11 October

09.00 – 12.15  Parallel Sessions

12.15 – 13.00  Packed Lunch available

13.00 – 15.00  Thrombosis and cancer workshop
Parallel Sessions

Monday 9 October 2006

Breast cancer – Sponsored by AstraZeneca
Hosted by Rob Coleman
University of Sheffield, Weston Park Hospital, UK

- **David Reid**
  University of Aberdeen, UK
  Breast cancer treatment induced bone loss (CTIBL): a draft prevention protocol

- **Andrew Tutt**
  Breakthrough Breast Cancer Research Centre, London, UK
  Triple negative breast cancer: how should we manage this ‘new’ disease?

- **Stephen Johnston**
  Royal Marsden Hospital, London, UK
  Recent progress with novel targeted therapies for breast cancer

- **J M Cuzick – Proffered Paper Presentation**
  Queen Mary University of London, UK
  Use of aromatase inhibitors for breast cancer prevention: rationale and current status of IBIS-II

- **A Downing – Proffered Paper Presentation**
  University of Leeds, UK
  Survival from breast cancer: the effects of social deprivation and other prognostic factors

- **M Verril – Proffered Paper Presentation**
  University of Newcastle, UK
  Anglo-Celtic IV: an NCRN randomised phase 3 trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer

Demonstrating value: patients in cancer research
Hosted by Roger Wilson
NCRI Consumer Liaison Group, UK

- **Roger Wilson**
  NCRI Consumer Liaison Group, UK
  The NCRI Consumer Likation Group - partnership is dynamic

- **Deborah Collyar**
  Patient Advocates in Research, National Cancer Institute, USA
  Patient advocates in research: transforming medical research into better results for people

- **Norman Scherzer**
  The Life Raft Group, USA
  Patient-led research
John Sitzia  
Worthing and Southlands Hospital Trust, UK  
Consumer involvement in cancer research networks: findings from a formative evaluation of the Consumer Research Panels pilot project

Diet and cancer  
Hosted by Sheila Bingham  
MRC Dunn Human Nutrition Unit, UK

- **Elio Riboli**  
  Imperial College London, UK  
  Obesity and the metabolic syndrome: the EPIC study

- **Arthur Schatzkin**  
  National Cancer Institute, USA  
  Dietary fat and breast cancer: new life for an old hypothesis

- **Sheila Bingham**  
  MRC Centre for Nutrition in Cancer Epidemiology Prevention and Survival and MRC Dunn Human Nutrition Unit, Cambridge, UK  
  Diet and colorectal cancer: epidemiology and mechanisms

- **B E Foreman – Proffered Paper Presentation**  
  University of Leicester, UK  
  Effect of the spice constituent Curcumin on G2/M cell cycle-related proteins

Epigenetics and methylation  
Hosted by Wolf Reik  
Babraham Institute, Cambridge, UK

- **Wolf Reik**  
  Babraham Institute, Cambridge, UK  
  Molecular mechanisms of epigenetic reprogramming in mammalian development

- **Joseph Costello**  
  University of California, San Francisco, USA  
  Genome-epigenome interactions in human tumourigenesis

- **Robert Brown**  
  CR-UK Beatson Laboratories, University of Glasgow, UK  
  CpG island DNA methylation profiling and modulation of drug resistance by epigenetic therapiess

- **Susan Clark**  
  Garvan Institute of Medical Research, Sydney, Australia  
  Epigenetic silent neighbourhoods in cancer cells

- **I Stancheva – Proffered Paper Presentation**  
  Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK  
  Regulation of epigenetic gene silencing by SUMO and PIAS proteins
Haemato-oncology – Sponsored by Novartis
Pharmaceuticals UK Limited
Hosted by Bryan Young
Barts and The University of London School of Medicine and Dentistry, UK

- Peter Valk
  Erasmus University Medical Center, Rotterdam, The Netherlands
  Genome-wide approaches to define new genetic identities in acute myeloid leukaemia

- Bryan Young
  Barts and The University of London School of Medicine and Dentistry, UK
  The application of large scale genotype analysis to acute myeloid leukaemia

- Gareth Morgan
  Institute of Cancer Research, Sutton, UK
  Integration of global SNP-based mapping and expression arrays reveals key mechanisms and genes important in the pathogenesis of multiple myeloma

- John Gribben
  Barts and The University of London School of Medicine and Dentistry, UK
  Transcriptional consequences of B cell receptor cross-linking in healthy and malignant B cells

High throughput SNP screening for the identification of cancer genes – Sponsored by Illumina
Hosted by Malcolm Dunlop
MRC Human Genetics Unit, UK

- Rhian Gwilliam
  The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
  Scanning the genome for genetic determinants of complex traits

- Malcolm Dunlop
  MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
  Mapping complex traits in colorectal cancer

- Paul Pharoah
  CR-UK Department of Oncology, Strangeways Research Laboratory, Cambridge, UK
  A genome-wide association study in breast cancer

- David L Barker
  Illumina Inc., San Diego, USA
  Human cancer cells, normal adult cells, somatic stem cells and embryonic stem cells have distinct DNA methylation signatures

- Panel discussion
Imaging
Hosted by Eric Aboagye
Imperial College School of Medicine, UK
- **David Plwnica-Worms**
  Washington University School of Medicine, USA
  Spying on cancer with genetically encoded imaging reporters
- **Eric Aboagye**
  Hammersmith Hospital, Imperial College London, UK
  *In vivo* imaging of targeted therapies by positron emission tomography
- **Anwar Padhani**
  Mount Vernon Hospital, Northwood, Middlesex, UK
  MRI in pre-clinical and clinical trials of anti-vascular treatments
- **V R Bulusu – Proffered Paper Presentation**
  Addenbrookes Hospital, Cambridge, UK
  Size does not matter! Patterns of response and progression in patients (pts) with inoperable and metastatic gastro intestinal stromal tumours (GISTS) on imatinib mesylate (IM)

NCRI Clinical Study Group – Colorectal cancer
Hosted by John Scholefield
University Hospital Nottingham, UK
- **John Scholefield**
  University Hospital Nottingham, UK
  Welcome and introduction
- **Seizing the research opportunities of the National Screening Programme for bowel cancer:**
  **Bob Steele**
  University of Dundee, UK
  The programme and the clinical research opportunities
  **Ian Tomlinson**
  CR-UK London Research Institute, UK
  Genetic opportunities
  Comments, questions and discussion
- **Translational research: predictive markers for therapy**
  **David Kerr**
  University of Oxford, UK
  Predicting benefit from adjuvant therapy: QUASAR and QUASAR2
  **Matt Seymour**
  University of Leeds, UK
  Predicting response to chemotherapy: lessons from FOCUS
  **Tim Maughan**
  Wales Cancer Trials Network, Section of Clinical Oncology, Velindre Hospital, Cardiff, UK
  Predicting response to EGFR therapy: the COIN, PICCOLO, XERXES and New Epoch trials
  Comments, questions and discussion
Surgical studies:

Bob Steele/John Monson
University of Dundee, UK/ Academic Surgical Unit, Castle Hill Hospital, Cottingham, Hull, UK
The quality of surgery in the CR07 trial

Dion Morton
University of Birmingham, UK
New trials in surgical therapy: e.g. FOXTROT

NCRI Clinical Study Group – Head and neck cancer
Hosted by Martin Robinson
Weston Park Hospital, UK

- Chris Boshoff
  Wolfson Institute for Biomedical Research, University College London, UK
  New agents

- Jayne Franklin
  University of Birmingham, UK
  Thyroid trials

- Chris Nutting
  Institute of Cancer Research, Royal Marsden Hospital, London, UK
  Radiotherapy studies

- Martin Birchall
  University of Liverpool, UK
  Surgical studies

NCRI Clinical Study Group – Lung cancer
Hosted by Tim Eisen
University of Cambridge, UK

- Tim Eisen
  University of Cambridge, UK
  Overview and the trials development pathway

- Stephen Falk
  Bristol Oncology and Haematology Centre, UK
  Rare Tumours’ Subgroup review

- David Ferry
  Black Country Cancer Research Network, The Royal Wolverhampton Hospitals NHS Trust, UK
  Advanced Disease Subgroup review

- Allan Price
  Western General Hospital, University of Edinburgh, UK
  LORD Subgroup review

- John Field
  University of Liverpool Cancer Research Centre, UK
  Translational Subgroup review

- Mick Peake
  Glenfield Hospital, University Hospitals of Leicester NHS Trust, UK
  SCEPTRE Subgroup review
o David Waller
   Glenfield Hospital, University Hospitals of Leicester NHS Trust, UK
   Mesothelioma Subgroup review

o Tim Eisen
   University of Cambridge, UK
   Discussion

NCRI Informatics
Hosted by Richard Begent
Royal Free and University College Medical School, UK

  o Robin Clark
     NCRI Informatics Coordination Unit, London, UK
     NCRI Informatics: How did we get here and where are we going?

  o Kenneth Buetow
     National Cancer Institute Centre for Bioinformatics, Bethesda, USA
     The cancer Biomedical Informatics Grid (caBIG™): enabling the patient-centric molecular medicine revolution

  o Monica Jones
     Animo Consultancy Ltd, UK
     Reducing the burden of information provision and data collection: a 21st century challenge

  o James Brenton
     Hutchison/MRC Research Centre, Cambridge, UK
     CancerGrid: tools for tissue-based research from clinical trials

  o Phil Quirke
     University of Leeds, UK
     Twenty first century clinical trials - a multidisciplinary approach

  o P D Lewis – Proffered Paper Presentation
     Swansea University, UK
     Mining cancer: data analysis needs standards too

Paediatric oncology – Translational biology
Hosted by Andy Pearson
Institute of Cancer Research, Royal Marsden Hospital, UK

  o Richard Gilbertson
     St Jude’s Children’s Research Hospital, Memphis, USA
     Translational biology and paediatric neuro-oncology: old news to deaf ears?

  o Janet Shipley
     Institute of Cancer Research, Sutton, UK
     Significance of specific genomic amplification events in rhabdomyosarcomas

  o Sten Eirik W Jacobsen
     Lund Stem Cell Center, Lund University, Sweden
     Identity and cellular origin of leukaemic stem cells
New therapy concepts for neuroblastoma: successful in vitro results with small-molecule MDM2 antagonist nutlin-3 and the search for new molecular targets using genome wide analysis of tumour cells and foetal neuroblasts

Promoting early presentation of cancer
Hosted by Amanda Ramirez
St Thomas’ Hospital, Adamson Centre for Mental Health, UK

Jane Wardle
University College London, UK
Improving uptake of cancer screening

Amanda Ramirez
St Thomas’ Hospital, Adamson Centre for Mental Health, Institute of Psychiatry/Kings College London, UK
Promoting early presentation of breast cancer

Lisa Cohen
West of Scotland Cancer Awareness Project, University of Strathclyde, UK
Spreading the word about mouth cancer

Targeting DNA damage and repair for new drug discovery
Hosted by Michelle Garrett
Institute of Cancer Research, Sutton, UK

Thomas Helleday – The BACR AstraZeneca Frank Rose Young Scientist Award Lecture
Institute for Cancer Studies, University of Sheffield, UK
DNA replication repair: from molecular insights towards new approaches to anti-cancer therapy

Johann de Bono
Institute of Cancer Research, Sutton, UK
A first in man Phase I trial involving biologic endpoints of the oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours with and without BRCA mutation

Roger Griffin
Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK
DNA damage-activated kinases as targets for cancer therapy

H D Thomas – Proffered Paper Presentation
Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK
Preclinical selection of a PARP inhibitor for clinical trial
**Tumour cell migration and invasion**

Hosted by Margaret Frame  
Beatson Institute for Cancer Research, Glasgow, UK

- **Margaret Frame**  
  Beatson Institute for Cancer Research, Glasgow, UK  
  *New functions of focal adhesion kinase; defining its role in cancer development and a new function for the FERM domain*

- **Inke Näthke**  
  University of Dundee, UK  
  *Cytoskeletal regulation in cell migration by the adenomatous polyposis coli protein*

- **Owen Sansom**  
  Beatson Institute for Cancer Research, Glasgow, UK  
  *c-Myc deletion and K-Ras activation modify cell migration and invasion of Apc deficient cells in vivo*

- **Eduard Batlle**  
  Institute for Research in Biomedicine, Barcelona, Spain  
  *Epithelial cell sorting and colorectal cancer suppression through EphB-ephrinB interactions*

- **Albert Reynolds**  
  Vanderbilt University School of Medicine, Nashville, USA  
  *Novel roles for p120 in Rac-dependant inhibition of Rho and in contact inhibition of cell growth*

- **J Sturge - Proffered Paper Presentation**  
  Imperial College London, UK  
  *Recycling endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly during tumour cell migration*

---

**Tuesday 10 October 2006**

**Advances in upper GI cancer**

Hosted by John Neoptolemos  
Royal Liverpool University Hospital, UK

- **Max Bachem**  
  University of Ulm, Germany  
  *On the role of stellate cells in pancreas cancer*

- **Rebecca Fitzgerald**  
  Hutchison/MRC Research Centre, Cambridge, UK  
  *Screening and surveillance for upper GI neoplasia*

- **Michael Goggins**  
  The Johns Hopkins Medical Institutions, Baltimore, USA  
  *Molecular markers of pancreatic neoplasia*
- **A Sultana - Proffered Paper Presentation**
  University of Liverpool, UK
  Meta-analysis of the management of locally advanced and metastatic pancreatic cancer

- **P Monaghan - Proffered Paper Presentation**
  Cancer Epidemiology and Prevention Research Group, Department of Epidemiology, Queen's University, Belfast, UK
  Factors influencing entry into routine surveillance for patients with Barrett’s Oesophagus: the Northern Ireland Barrett’s Oesophagus Register

**Behaviour change for cancer prevention**
Hosted by Jane Wardle
University College London, UK

- **Robert West**
  CR-UK Health Behaviour Unit, University College London, UK
  How can the UK possibly get its smoking prevalence below 20%?

- **Victor J Strecher**
  University of Michigan Comprehensive Cancer Center, USA
  Cancer prevention and the internet

- **Greg Beales**
  Cabinet Office, London, UK
  Personal responsibility and behaviour change

- **T Coleman – Proffered Paper Presentation**
  University of Nottingham, UK
  Impact of contractual financial incentives on the ascertainment and management of smoking in primary care

**Cancer genetics**
Hosted by Nazneen Rahman
Institute of Cancer Research, Sutton, UK

- **Nazneen Rahman**
  Institute of Cancer Research, Sutton, UK
  DNA repair genes and breast cancer predisposition – a complex web of high and low penetrance susceptibility alleles

- **Julian Sampson**
  Institute of Medical Genetics, Cardiff University, UK
  MUTYH, base excision repair and colorectal cancer

- **Michael Stratton**
  Wellcome Trust Sanger Institute, Cambridge, UK
  The mutational landscape of human cancers
Combined modality therapy –
Organised by the British Oncological Association
Hosted by Rob Coleman
University of Sheffield, Weston Park Hospital, UK
  - Cornelis JH van de Velde and Tim S Maughan
    Leiden University Medical Centre, The Netherlands and Velindre Hospital, Cardiff University, UK
    Is surgery all you need for rectal cancer?
  - Andrew Hayes and Martin H Robinson
    Royal Marsden Hospital, UK and Weston Park Hospital, Sheffield, UK
    Do soft tissue sarcoma patients need one or two local treatment modalities?
  - Adrian Crellin
    Cookridge Hospital, Leeds, UK
    One - two - three - four modalities to cure oesophageal and gastric cancer?

DNA repair
Hosted by Simon Boulton
CR-UK London Research Institute, UK
  - Kevin Hiom
    MRC Laboratory of Molecular Biology, Cambridge, UK
    The molecular functions of BRCA1 in DNA repair and cancer predisposition
  - Keith Caldecott
    Genome Damage and Stability Centre, University of Sussex, UK
    Chromosomal single-strand break repair and neurodegenerative disease
  - James Turner
    National Institute for Medical Research, London, UK
    The role of BRCA1 in spermatogenesis
  - J D Ward - Proffered Paper Presentation
    CR-UK London Research Institute, Clare Hall Laboratories, UK
    The role of the single C. elegans RAD51 paralog in repair of impeded replication forks

Drug development: target validation and biomarkers
Hosted by Sir David Lane
Institute of Molecular and Cell Biology, Singapore and University of Dundee, UK
  - Sir David Lane
    Institute of Molecular and Cell Biology, Singapore and University of Dundee, UK
    Cell based screening for activators of the p53 response
  - Mark Rolfe
    Millennium Pharmaceuticals Inc, USA
    The discovery and development of VELCADE, a novel proteasome inhibitor for cancer therapy
Ravi Salgia  
University of Chicago, USA  
Role of c-Met in lung cancer

Eric Raymond  
Service Inter-Hospitalier de Cancérologie Bichat-Beaujon, Hôpital Beaujon, Paris, France  
Validation of VEGFR and mTOR as molecular targets for cancer therapeutics: past history and future clinical development of sunitinib malate (SU11248) and temsirolimus (CCI-779) using molecularly oriented translational researches

Spiros Linardopoulos - Proffered Paper Presentation  
Institute of Cancer Research, UK  
Aurora-A kinase inhibition downregulates NF-kappaB and sensitises human tumour cells to chemotherapeutic agents

NCRI Clinical Studies Development Group – Complementary therapies  
Hosted by Susie Wilkinson  
Marie Curie Palliative Care Research and Development Unit, London, UK

Leslie Walker  
Institute of Rehabilitation and Oncology Health Centres, University of Hull/Hull and East Yorkshire Hospitals NHS Trust, UK  
A randomised controlled trial of reflexology in women with early stage breast cancer

Alexander Molassiotis  
University of Manchester, UK  
Managing cancer-related fatigue with acupuncture: a pilot randomised trial

Debbie Sharp and Maggie Evans  
University of Bristol, UK  
Men with cancer: is their use of complementary and alternative medicine a response to needs un-met by orthodox health care?

Dai Roberts and Ann Caress  
St Anne’s Hospice, Manchester, UK and University of Manchester, UK  
A multi-centre evaluation of complementary therapy provision for patients with cancer – access, expectations and indications for therapy

Tony Leathem  
University College London, UK  
Effects of diet, complementary medicines and lifestyle on breast cancer progression: the DietCompLyf trial

Susie Wilkinson  
Marie Curie Palliative Care Research and Development Unit, London, UK  
Conclusion
NCRI Clinical Study Group – Lymphoma
Sponsored by Roche
Hosted by Peter Johnson
CR-UK Wessex Regional Medical Oncology Unit, University of Southampton, UK
- Andrew Jack
  Birmingham Nuffield Hospital, UK
  New insights into the biology of large cell lymphoma
- Michael Pfreundschuh
  University of Saarland, Homburg, Germany
  Progress in the treatment of DLBCL: a German perspective
- George Mikhaeel
  Guy’s and St Thomas’ Hospital, London, UK
  PET imaging in the management of large cell lymphoma
- Tim Illidge
  Paterson Institute for Cancer Research, Manchester, UK
  Using radioimmunotherapy in large cell lymphoma

NCRI Clinical Studies Development Group – Teenage and young adults
Hosted by Jeremy Whelan
Middlesex Hospital, University College London Hospitals NHS Trust, UK
- Jeremy Whelan
  Middlesex Hospital, University College London Hospitals NHS Trust, UK
  Why do we need an NCRI group for teenagers and young adults?
- Jill Birch
  CR-UK Paediatric and Familial Cancer Research Group, University of Manchester, UK
  The national profile of cancers in teenagers and young adults in England
- Lorna Fern
  NCRI Teenage and Young Adults Clinical Studies Development Group, UK
  Inclusion of teenagers and young adults in clinical trials in England – How are we doing?
- Clare Rowntree
  University Hospital of Wales, Cardiff, UK
  How should young adults with acute lymphoblastic leukaemia be treated?
- Kelly Denver
  University College London, UK
  Why hospital environments are important to teenagers and young adults
- TYA Working parties:
  Michael Hawkins
  University of Birmingham, UK
  Survivorship: patient and doctor perspectives
Ovarian cancer
Hosted by Hani Gabra
West London Gynaecological Cancer Centre, Imperial College London, UK

- Hani Gabra
  West London Gynaecological Cancer Centre, Imperial College London, UK
  The WWOX gene in epithelial ovarian cancer

- Honami Naora
  MD Anderson Cancer Centre, University of Texas, USA
  The paradox of ovarian cancers: developmental patterning in the wrong context?

- James Brenton
  University of Cambridge, UK
  Functional genomics studies in ovarian cancer

- Fran Balkwill
  Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK
  Translating our knowledge of the cytokine network of ovarian cancer into new cancer treatments

- M Spears - Proffered Paper Presentation
  Cancer Research UK, University of Edinburgh Cancer Research Centre, UK
  The expression and function of LSAMP in epithelial ovarian cancer

Paediatric oncology – Clinical trials
Hosted by Andy Pearson
Institute of Cancer Research, Royal Marsden Hospital, UK

- Andy Pearson
  Institute of Cancer Research, Royal Marsden Hospital, UK
  A new international therapeutic classification for neuroblastoma

- Carolyn Freeman
  McGill University, Montreal, Canada
  The Children's Oncology Group CNS studies: strategy, progress and plans for the future

- James Nachman
  University of Chicago Children’s Hospital, USA
  Acute lymphoblastic leukaemia 2006: the COG paradigm
o **Ian Lewis**  
Leeds Teaching Hospital, UK  
EICESS-92: A successful collaborative intergroup trial in Ewing’s Sarcoma with unexpected results

o **D Pang - Proffered Paper Presentation**  
University of Manchester and Cancer Research UK, Manchester, UK  
Cancer incidence in relatives of children with osteosarcomas and chondrosarcomas

---

**Places of care near the end of life**  
Hosted by Sheila Payne  
University of Sheffield, UK

o **Julia Addington-Hall**  
University of Southampton, UK  
Dying at home in the UK: ideology and evidence

o **Joan Teno**  
Brown Medical School, Brown University, USA  
Bereaved family member perspectives on the last place of care in the USA

o **Philip Larkin**  
Centre for Nursing Studies, National University of Ireland, Eire  
Transition towards palliative care: an exploration of its meaning for advanced cancer patients in Europe

o **E Davies - Proffered Paper Presentation**  
King's College London, UK  
How is place of death changing and what affects it? Analysis of service and registry data

o **C J N Meystre - Proffered Paper Presentation**  
Warwick Hospital, UK  
Does poorer educational status influence engagement with a palliative care needs assessment survey sent by post to patients diagnosed with incurable lung cancer?

---

**Prostate cancer**  
Hosted by Norman Maitland  
YCR Cancer Research Unit, University of York, UK

o **Charles G Drake**  
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA  
Immunotherapy for prostate cancer: clinical and basic science perspectives

o **Angus Dalgleish**  
St George’s Hospital Medical School, UK  
Immunotherapy and prostate cancer
- **Christian Ottensmeier**
  University of Southampton, UK
  DNA vaccination for prostate cancer: from the laboratory to the bedside

- **A Cooper - Proffered Paper Presentation**
  University of Portsmouth, UK
  Prostasomes possess properties compatible with their influencing the course of neoplastic prostate disease

- **Luke Gaughan - The BACR Translational Research Award Lecture**
  Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK
  Novel mechanisms of androgen receptor regulation in prostate cancer

---

**Stem cells in cancer**
Hosted by Rob Clarke
Christie Hospital, Manchester, UK

- **Robert Clarke**
  Christie Hospital, Manchester, UK
  Regulation of human breast stem cells

- **Anne Collins**
  Yorkshire Cancer Research Unit, University of York, UK
  α2[hi]/CD133[+] prostate cancer stem cells from human tumours are highly tumourigenic and metastatic *in vivo*

- **Maarten van Lohuizen**
  The Netherlands Cancer Institute, Amsterdam, The Netherlands
  Polycomb repressors controlling stem cell fate: implications for cancer and development

- **K L Britt – Proffered Paper Presentation**
  Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, UK and Garvan Institute of Medical Research, Sydney, Australia
  Mouse mammary epithelial stem cell lineage analysis

---

**Survivorship**
Hosted by Nigel Palmer
NCRI Consumer Liaison Group, UK

- **Ziv Amir**
  Macmillan Research Unit, University of Manchester, UK
  Can you afford to have cancer?

- **Maggie Crowe**
  Royal United Hospital, Bath, UK
  Unidentified or unmet: what are the supportive care needs of people following cancer treatment?
• **Noreen Aziz**
  Office of Cancer Survivorship, National Cancer Institute, Bethesda, USA
  Cancer survivorship: challenges and opportunities of an evolving research area

• **A M Campbell - Proffered Paper Presentation**
  Strathclyde University, Glasgow, UK
  A randomised controlled trial of a supervised group exercise programme as a rehabilitation treatment for women receiving treatment for early stage breast cancer

---

**The future of UK cancer intelligence – Organised by the United Kingdom Association of Cancer Registries**

Hosted by Mike Richards
National Cancer Director for England, UK

• **Henrik Møller**
  Thames Cancer Registry and Kings College London, UK
  The burden of cancer in England in 2020

• **Chris Carrigan**
  National Cancer Registry, UK
  Changing the delivery of cancer information, intelligence and informatics

• **Ken Lloyd and Sue Forsey**
  Thames Valley Cancer Network, UK
  How should we audit and monitor the delivery of cancer services?

• **David Forman**
  Northern and Yorkshire Cancer Registry and University of Leeds, UK
  Extending the uses of cancer information

---

**The immune system: a barrier to cancer?**

Hosted by Caetano Reis e Sousa
CR-UK London Research Institute, UK

• **Adrian Hayday**
  Guy’s, King’s and St Thomas’ School of Medicine, UK
  Helping the natural capacity of unconventional T cells to fight tumours

• **Cornelis J M Melief**
  Leiden University Medical Centre, The Netherlands
  Immunotherapy of established papilloma virus-induced (pre-)malignant lesions in mice, rabbits and patients

• **Vincenzo Cerundolo**
  Weatherall Institute of Molecular Medicine, University of Oxford, UK
  Harnessing iNKT cells in cancer vaccines
Wednesday 11 October 2006

**Addressing patients’ care needs through nurse-led research**
Hosted by Alison Richardson
Florence Nightingale School of Nursing and Midwifery, King’s College London, UK

- **Barbara Given**  
  Michigan State University, USA  
  Managing cancer patients’ symptoms through nurse-delivered behavioural interventions
- **Nora Kearney**  
  University of Stirling, UK  
  Is nursing’s future remote? Advancing symptom management through the application of technology
- **Karen Cox**  
  University of Nottingham, UK  
  Enhancing early phase trial management: A randomised controlled trial of nurse-managed trial conclusion
- **S Faithfull - Proffered Paper Presentation**  
  University of Surrey, UK  
  Evaluation of a structured care telephone follow-up service for women with ovarian cancer post treatment

**Challenges in diagnosis and prevention of cancer in primary care**
Hosted by Janet Darbyshire and Mike Richards  
MRC Clinical trials Unit, London, UK and National Cancer Director, St Thomas’ Hospital, UK

- **Una Macleod**  
  University of Glasgow, UK  
  Pre-hospital delay in cancer diagnosis: what can we learn from the literature?
- **Kurt Stange**  
  Case Western Reserve University, USA  
  Cancer prevention among the competing demands and opportunities of primary care
- **David Weller**  
  University of Edinburgh, UK  
  Promoting earlier diagnosis of cancer in primary care
- **Willie Hamilton**  
  University of Bristol, UK  
  The CAPER studies
Chemical biology in relation to cancer
Hosted by Stephen Neidle and Roger Griffin
University of London, UK and University of Newcastle upon Tyne, UK
  o Tarun Kapoor
    Rockefeller University, USA
    Using kinase inhibitors to probe cell division mechanisms
  o Hagan Bayley
    University of Oxford, UK
    Prospects for rapid sequencing of large genomes
  o Rodolfo Marquez
    University of Dundee, UK
    Biological chemistry approaches to the synthesis of PDK1 and PKB inhibitors
  o Stephen Neidle
    University of London, UK
    The chemical biology of telomere targeting agents
  o Ian Collins
    CR-UK Centre for Cancer Therapeutics, Institute of Cancer Research, UK
    Combinatorial and structure-based approaches to the discovery of new inhibitors of PKB

Chemoprevention
Hosted by Andy Gescher
University of Leicester, UK
  o James Crowell
    National Cancer Institute, Bethesda, USA
    Identifying and developing novel, new chemopreventive agents
  o Fritz H Schröder
    Erasmus Medical Centre, Rotterdam, The Netherlands
    Chemoprevention in prostate cancer - results of phase II studies and growth inhibition in nude mice
  o Maggie Manson
    University of Leicester, UK
    The potential for dietary agents in cancer prevention and therapy
  o R Lal - Proffered Paper Presentation
    CR-UK London Research Institute, UK
    Prevention of MEK1-activated tumour formation by immunosuppression of the host microenvironment
Colorectal cancer
Hosted by Alan Clarke
Cardiff University, UK
  - Ian Tomlinson
    CR-UK London Research Institute, UK
    Loss of heterozygosity in human and mouse colorectal tumours
  - Alan Clarke
    Cardiff University, UK
    Investigating early neoplastic changes in the intestine through conditional deletion in the mouse
  - Riccardo Fodde
    Erasmus University Medical Center, The Netherlands
    Stemness, signal transduction and genetic instability in intestinal cancer: new bottle, old wine
  - G Smith - Proffered Paper Presentation
    University of Dundee, Scotland, UK
    K-Ras mutations define a distinct genetic pathway to colorectal cancer, associated with reduced patient survival
  - W Kolch - Proffered Paper Presentation
    Beatson Institute for Cancer Research, Glasgow, UK
    RKIP expression in colorectal cancer predicts metastatic recurrence and overall survival

CR-UK Development Committee workshop – Sponsored by Cancer Research UK
Hosted by Herbie Newell
Cancer Research UK, UK
  - Clive Stanway
    Wolfson Institute, University College London, UK
    The CRT Development Labs and their role in the Development Committee
  - Steve Wedge
    AstraZeneca, UK
    Current challenges in identifying and developing small molecule cancer therapeutics
  - Michelle Garrett,
    CR-UK Centre for Cancer Therapeutics, Institute of Cancer Research, UK
    What makes a good drug target and the drug development process
  - Caroline Dive
    Cellular and Molecular Pharmacology Group, Paterson Institute for Cancer Research, Manchester, UK
    When should I apply to the Development Committee for funding?"
Workshop panel
How to successfully apply for a Development Committee grant
Dummy applicants: Herbie Newell and Business Manager
‘Example of a bad DC proposal’; Tony Raynham, Tony Raynham and Business Manager ‘Example of a good DC proposal’
Panel: Caroline Dive (Chair), Michael Olson, Peter Fischer, Clive Stanway, Phil L’Huilier

Future directions in oncology imaging -
Sponsored by The Royal College of Radiologists
Hosted by Rodney Reznek
Institute of Cancer, Barts and the London, UK

- Lawrence Schwartz
  Memorial Sloan-Kettering Cancer Center, USA
  Imaging as a biomarker: emerging roles and challenges

- Rodney Reznek
  Institute of Cancer, Barts and the London, UK
  Pelvic cancer: How MRI helps to develop new treatments

- Anwar Padhani
  Mount Vernon Hospital, UK
  Angiogenesis imaging and tumour response

- Laura M Kenny – ACP McElwain Prize Lecture
  Imperial College London, UK
  $[^{18}F]Fluorothymidine$ positron emission tomography - a novel method to study cell proliferation in vivo

Immunotherapy
Hosted by Christian Ottensmeier
University of Southampton, UK

- Iacob Mathiesen
  Inovio AS, Norway
  Gene delivery by electroporation: applications for immune therapy

- Hans Stauss
  Royal Free Hospital, University College London, UK
  Mechanisms of impaired T cell responses against tumour-associated antigens

- Ugur Sahin
  Johannes Gutenberg University, Germany
  A pharmacological approach for the development of new recombinant vaccines

- J G Chai - Proffered Paper Presentation
  Imperial College London, UK
  Strategies for overcoming naturally occurring unresponsiveness to HY in CBA mice
- E J Cheadle - Proffered Paper Presentation
  Paterson Institute for Cancer Research, Manchester, UK
  Therapeutic efficacy of engineered T cells targeting CD19 in a B-cell lymphoma model

- J C Gray - Proffered Paper Presentation
  University of Southampton, UK
  Overcoming tolerance with combinations of immunostimulatory monoclonal antibodies

Infection and cancer – Supported by an unrestricted educational grant from GlaxoSmithKline
Hosted by Lawrence Young
CR-UK Institute for Cancer Studies, University of Birmingham, UK
- Lawrence Young
  CR-UK Institute for Cancer Studies, University of Birmingham, UK
  EBV and cellular transformation: modulation of cytokine and cell signalling pathways to promote virus persistence and oncogenesis
- Richard Longnecker
  Northwestern Medical School, Chicago, USA
  How to enter B and epithelial cells: lessons from Epstein-Barr virus
- Dennis J McCance
  Centre for Cancer Research and Cell Biology, Queen’s University, UK
  AKT - a therapeutic target for epithelial cancers caused by HPV
- David Blackbourn
  CR-UK Institute for Cancer Studies, University of Birmingham, UK
  KSHV immune modulation and the evolution of a potential anti-inflammatory therapeutic

- M Vockerodt – Proffered Paper Presentation
  Cancer Research UK Institute for Cancer Studies, University of Birmingham, UK
  The EBV-encoded latent membrane protein-1 imposes a Hodgkin/Reed-Sternberg-like gene expression signature when expressed in germinal centre B cells

- M S Campo – Proffered Paper Presentation
  Institute of Comparative Medicine, University of Glasgow, UK
  Papillomavirus E5 proteins and MHC class I: a common way to evade the immune response

Lung cancer
Hosted by John Field
University of Liverpool Cancer Research Centre, UK
- James Mulshine
  Rush University Medical Centre, Chicago, USA
  Update on early lung cancer management
- **John Field**  
  University of Liverpool Cancer Research Centre, UK  
  Developing a molecular epidemiological risk prediction model
- **Paolo Boffetta**  
  International Agency for Cancer Research, Lyon, France  
  Lung cancer due to occupational exposures
- **M Linch - Proffered Paper Presentation**  
  Royal Marsden Hospital, Sutton, Surrey, UK  
  An audit of the use of pemetrexed for the treatment of malignant pleural mesothelioma in an expanded access programme compared to previous experience with MVP (mitomycin C, vinblastine and cisplatin)
- **G M Jacobson - Proffered Paper Presentation**  
  University of Liverpool, UK  
  Downregulation of REST/NRSF induces transcription of multiple genes in lung cancer that may contribute to tumour phenotype and provide markers for clinical disease
- **A Alzetani - Proffered Paper Presentation**  
  Heart of England NHS Trust, Birmingham, UK  
  Serum proteomics in lung cancer

**NCRI Clinical Studies Development Group – Psychosocial Oncology**  
Hosted by Mike Baum  
University College London, UK
- **Mike Baum**  
  University College London, UK  
  Introduction and The remit of the Group and its subgroups
- **Julia Brown**  
  University of Leeds, UK  
  Quality of life aspects of big trials
- **Penny Hopwood**  
  Christie Hospital NHS Trust, Manchester, UK  
  Quality of life data from START and TACT trials
- **Elaine Rankin**  
  Ninewells Hospital, Dundee, UK  
  Local research in Dundee
- **Louise Jones**  
  Marie Curie Palliative Care Research Unit, London, UK  
  Local research in London/at the Royal Free
- **Galina Velikova**  
  CR -UK Clinical Centre, University of Leeds, UK  
  The development and funding of a particular study
- **Noreen Aziz**  
  Office of Cancer Survivorship, National Cancer Institute, USA  
  Cancer survivorship, lifestyle interventions and the teachable moment
Radiobiology – Sponsored by the British Oncological Association
Hosted by Penny Jeggo
Genome Damage and Stability Centre, University of Sussex, UK

- Penny Jeggo
  Genome Damage and Stability Centre, University of Sussex, UK
  Essential role of non-homologous end-joining in the maintenance of haematopoietic stem cell function

- Katherine Vallis
  Princess Margaret Hospital, Toronto, Canada
  Molecule guided radiation therapy

- Rob Coppes
  University of Groningen, The Netherlands
  Stem cell therapy to reduce radiation-induced toxicity

- Gillian Tozer
  University of Sheffield, UK
  Imaging tumour vascular morphology and function for assessing therapeutic efficacy

- K M Prise - Proffered Paper Presentation
  Gray Cancer Institute, Northwood, UK
  Cytokine-dependent cell signalling in response to targeted irradiation

- S P Wheatley - Proffered Paper Presentation
  University of Sussex, UK
  Separating the anti-apoptotic and mitotic roles of survivin

Research information for patients and the public
Hosted by Derek Stewart
NCRI Consumer Liaison Group, UK

- Matthew Hallsworth
  UK Clinical Research Collaboration, UK
  Public awareness of clinical research

- R Owen – Proffered Paper Presentation
  3 Counties Cancer Network, Gloucestershire, UK
  Deciding whether to take part in cancer clinical trials: patient and staff perspectives

- Jessica Corner, Claire Dawson, Karen Poole and members of the NCRI CLG
  Macmillan Cancer Relief, UK; Institute of Cancer Research, Sutton, UK; Surrey, West Sussex and Hampshire Cancer Research Network, UK and NCRI Consumer Liaison Group, UK
  Patients in research - sharing information and resources

- Richard Stephens
  NCRI Consumer Liaison Group, UK
  Patient information sheets
Tissue banks
Hosted by Brian Clark
onCoreUK, London, UK

- **Brian Clark**
onCoreUK, London, UK
  Biosample and information banking for cancer research

- **Manuel Morente**
  Spanish National Tumour Bank Network, Madrid, Spain
  Tumour bank networking: the Spanish design

- **Peter Riegman**
  Erasmus Medical Centre Tissue Bank, Rotterdam, The Netherlands
  Creating TuBaFrost: a European human frozen tumour tissue bank

- **Sandy Mather**
  Human Tissue Authority, London, UK
  Establishing a regulatory, advisory and licensing environment to foster research tissue banking

- **G T Thomas - Proffered Paper Presentation**
  South West Wales Cancer Institute, Swansea, UK
  Quality assurance in a regional population based tumour bank
**Workshops**

**Sunday 8 October 2006**

**Cancer Recognised Research Group (RRG) workshop on molecular mechanisms of metastasis**
13:00 – 15.10

*Hosted by Charles Campbell and Stephanie McKeown*
Queen’s University Belfast, UK and University of Ulster, UK

- **Philip Rudland**
  The University of Liverpool, UK
  Keynote Lecture - Molecular mechanisms of metastasis

- **A H Devlin**
  Biomedical Science, University of Ulster, Coleraine, UK
  Expression of Cytochrome P450 1B1 protein in tumours: role of translational control

- **E A Dunlop**
  Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, UK
  Evidence of abnormal erythropoietin receptor downregulation in non-small cell lung carcinoma

- **G Collett**
  Department of Surgery, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK
  Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells

- **H Xu**
  Department of Surgery, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK
  Ligand-activated vitamin D receptor (VDR) modulates the neoplastic phenotype through osteopontin (OPN) and β-Catenin/LEF-1/TCF signalling

- General discussion
- Tea/Coffee

**Monday 9 October 2006**

**BACR educational workshop - Cancer drug discovery**
08.00 – 08.50

- **Michelle Garrett**
  Institute of Cancer Research, Sutton, UK

- **Andrew Westwell**
  Cardiff University, UK
Commercial workshop
A brave new world: the opportunity and practicality of targeted therapy in renal cell cancer and beyond
Sponsored by Bayer HealthCare
13:00 - 14:00
- Tim Eisen
  University of Cambridge, UK
  Tyrosine Kinase Inhibitors in 2006 - state of play
- Aslam Sohaib
  Institute of Cancer Research and Royal Marsden Hospital, London, UK
  How Should We Measure Efficacy of Tyrosine Kinase Inhibitors - is RESIST enough?
- Kim Edmonds
  Royal Marsden Hospital, London, UK
  Practicalities and Management - real life experience
- Paul Nathan
  Mount Vernon Cancer Centre, London, UK
  Future Directions - What questions remain?

Clinical Fellows’ careers workshop
14.00 – 15.00
Hosted by Nick Lemoine
Barts and The London School of Medicine and Dentistry, UK
- Alan Melcher
  CR-UK Clinical Centre, St James’ University Hospital, University of Leeds, UK
- Nick Lemoine
  Barts and The London School of Medicine and Dentistry, UK
- Simon Vincent
  Cancer Research UK, London, UK

Grant-writing workshop – Sponsored by Elsevier
14.00 – 15.00
Hosted by David Critchley
Cancer Research UK, London, UK
- Liz Simpson
  Imperial College School of Medicine, UK
- Margaret Frame
  Beatson Institute for Cancer Research, Glasgow, UK

PhD Students’ careers workshop – Finding a Post Doc position
Sponsored by Aegera
14.00 – 15.00
Hosted by Sally Leevers
CR-UK London Research Institute, UK
o Alison Lloyd
  MRC Laboratory for Molecular Cell Biology, University College London, UK
o Sir David Lane
  Institute of Molecular and Cell Biology, Singapore
o Birgit Lane
  Centre for Molecular Medicine, Singapore and University of Dundee, UK

Post Docs’ careers workshop – Sponsored by Aegera
14.00 – 15.00
Hosted by Caroline Dive
Paterson Institute for Cancer Research, UK
  o Keith Caldecott
    University of Sussex, UK
    Independent Fellowship to Senior Scientist
  o Andrew Walker
    AstraZeneca, UK
    Scientific Writing
  o Tanya Moore
    Cancer Research Technology, UK
    Intellectual Property in Science
  o Kat Arney
    Cancer Research UK, UK
    Scientific Journalism

Tuesday 10 October 2006

BACR educational workshop - Imaging of cancer targets
08.00 – 08.50
  o Eric Aboagye
    Imperial College London, UK
  o Kevin Francis
    Xenogen, USA

Commercial workshop
Novel microarray approaches to studying genome architecture
Sponsored by Affymetrix
13.00 – 14.00
  o Bryan D Young
    Bart's & The London School of Medicine, UK
    The use of Affymetrix GeneChip® Exon Arrays to investigate expression profiles in leukaemias

The objective of this workshop will be to demonstrate how ground-breaking discoveries in cancer research could be facilitated by the use of novel Affymetrix approaches to interrogate the genome. Recent advances in Affymetrix novel technologies for studying genome architecture will be discussed.
Careers in radiation related research: clinical and scientific – Organised by the Academic Clinical Oncology and Radiobiology Research Network (ACORRN)
14.00 – 15.00
Hosted by Pat Price
University of Manchester and ACORRN Steering Committee, UK
  - Gillian Heap
    University of Manchester, UK
  - Catharine West
    University of Manchester, UK
  - Cath Holborn
    Sheffield Hallam University, UK
  - Mary Tanay
    Royal Marsden Hospital, London, UK
  - Pat Price
    University of Manchester and ACORRN Steering Committee, UK

Women in science
14.00 – 15.00
Hosted by Clare Isacke
Breakthrough Breast Cancer Research Centre, UK
  - Ava Yeo
    CR-UK London Research Institute, UK
  - Inke Näthke
    University of Dundee, UK
  - Liz Simpson
    Imperial College School of Medicine, UK
  - Fiona Hemsley
    Cancer Research UK, UK

Wednesday 11 October 2006

Thrombosis and cancer workshop
13.00 – 15.00
Chaired by Rob Coleman and Rob Carpenter
University of Sheffield, Weston Park Hospital, UK and Barts and The London, UK
  - Annie Young
    3 Counties Cancer Network, UK
    Catheters and thrombosis: practical management
  - John Pasi
    Institute of Cell and Molecular Science, Bart’s and The London Medical School, UK
    Managing anticoagulation in the cancer patient
  - Ajay Akkar
    Queen Mary’s School of Medicine and Dentistry, London, UK
    Preventing venous thromboembolism in the cancer patient